



www.probiomics.com.au

**The Australian Stock Exchange Limited,
Companies Announcements Office
SYDNEY
Via: asxonline
20th May 2005**

BOARD CHANGES AND AIM LISTING

Probiomics Limited has accepted the resignation of the Chairman, Sir Victor Garland as a consequence of the Company's decision not to pursue an AIM listing in the U.K.

This decision has been made in view of the downturn in market conditions in the Biotechnology and Healthcare sectors both domestically and in the U.K.

Sir Victor was appointed a Director and Chairman in February 2005 in anticipation of, and as a requirement to have a U.K.- based Director for AIM admission.

OTHER BOARD CHANGES

Mr Bryan Gardiner who was appointed as a Director in February this year has been elected as Chairman of the Board to replace Sir Victor Garland.

Mr Geoffrey Wild who has been a Director of the Company since November 2003 has resigned.

Mr Patrick Ford a Sydney based stockbroker with Taylor Collison Limited has been appointed a Director of the Company. Mr Ford has an extensive history of capital raising and supplying advice to the Australian Biotechnology sector, and the Board welcomes his involvement.

ABOUT PROBIOMICS LIMITED (PCC)

Probiomics Ltd is an Australian biotechnology company developing proprietary probiotic and biomolecular technology for commercial applications in consumer health, functional foods and pharmaceutical products.

For further information contact refer to www.probiomics.com.au or phone:

Mr Kim Slatyer, CEO on 02/9209 4268

Probiomics Limited
(formally VRI BioMedical Limited)

Probiomics Limited
ACN 084 464 193 ABN 97 084 464 193
Suite G09, 1 Central Avenue, Australian Technology Park, Eveleigh, Sydney NSW 1430, Australia
Phone: +61 2 9209 4268 Fax: +61 2 9209 4256